Prova di fase I di un farmaco sperimentale contro il vaiolo
Uno studio esplorativo randomizzato, in doppio cieco, incrociato, di fase I sulla farmacocinetica di una singola dose orale di forma I rispetto alle capsule di forma V del composto anti-Orthopoxvirus ST-246® in volontari sani alimentati normalmente
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.
Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32809
- Orlando Clinical Research Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 18 to 50 years
- Available for clinical follow-up duration of study.
- Able/willing to give written consent.
- Good general health; no clinically significant medical history.
- Refrain from taking any medications from screening through 72 hours after last dose.
- Adequate venous access.
- PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
- Meet Lab Criteria within 28 days prior to receipt of drug.
- Negative pregnancy test
- Non smokers
- No alcohol or caffeine
- Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study
Exclusion Criteria:
-
Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
-
History of additional risk factors for Torsade de Pointes
-
Clinically significant abnormal ECG
-
Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
-
Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
-
History of any clinically significant conditions including:
- Asthma
- Diabetes mellitus
- History of thyroidectomy or thyroid disease
- Serious angioedema episodes
- Head trauma resulting in a diagnosis of TBI other than concussion
- Seizure or history of seizure
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
- Malignancy
-
Family history of idiopathic seizures
-
History or presence of neutropenia or other blood dyscrasia
-
Known Hepatitis B or Hepatitis C infection
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
-
Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
-
Known clinically significant chronic viral infection (or current clinically significant viral infection
-
History of frequent or severe headaches or migraines
-
Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
-
Woman who is pregnant or is breast-feeding or planning to become pregnant
-
On any concomitant medications
-
History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
-
Inability to swallow medication
-
Body Mass Index above 35 or below 18,
-
Current drug abuse or alcohol abuse.
-
Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
-
Clinically significant lactose intolerance
-
Received experimental drug within 30 days
-
Vaccination within 30 days
-
Total of more than 350 milliliters (mL) of blood drawn in 2 months
-
Treatment with any immunosuppressant or immunomodulatory medication in 3 months
-
Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
-
History or diagnosis that would affect absorption of study medication
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Group ST-246 Form I (followed by Form V)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Altri nomi:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Altri nomi:
|
|
Comparatore attivo: Group ST-246 Form V (followed by Form I)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Altri nomi:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax) |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Lasso di tempo: 4 weeks
|
Evaluated safety parameters included:
|
4 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Thomas C Marbury, MD, Orlando Clinical Research Center
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SIGA-246-005
- HHSN266200600014C (Altro numero di sovvenzione/finanziamento: NIAID)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .